Skip to main content

AngioDynamics, Inc. (ANGO)

NASDAQ: ANGO · IEX Real-Time Price · USD
27.51 1.75 (6.77%)
Oct 15, 2021 1:42 PM EDT - Market open
Market Cap1.00B
Revenue (ttm)297.77M
Net Income (ttm)-34.25M
Shares Out38.73M
EPS (ttm)-0.89
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume260,758
Open27.19
Previous Close25.76
Day's Range27.14 - 28.53
52-Week Range10.17 - 30.25
Beta0.86
AnalystsBuy
Price Target30.00 (+9.1%)
Est. Earnings Daten/a

About ANGO

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract...

IndustryHealth Care Equipment & Supplies
IPO DateMay 27, 2004
CEOJames Clemmer
Employees800
Stock ExchangeNASDAQ
Ticker SymbolANGO
Full Company Profile

Financial Performance

In 2021, AngioDynamics's revenue was $291.01 million, an increase of 10.17% compared to the previous year's $264.16 million. Losses were -$31.55 million, -81.08% less than in 2020.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for AngioDynamics stock is "Buy." The 12-month stock price forecast is 30.00, which is an increase of 9.07% from the latest price.

Price Target
$30.00
(9.07% upside)
Analyst Consensus: Buy

News

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.

2 weeks ago - Zacks Investment Research

Investors Cheer AngioDynamics' Q1 Beat, Raised FY22 Sales Outlook

AngioDynamics Inc  (NASDAQ: ANGO) reported a Q1 FY22 adjusted EPS loss of $(0.02), ahead of the consensus of $(0.04). Q1 sales increased 9.6% Y/Y to $77 million, beating the analyst consensus of $71.31 ...

2 weeks ago - Benzinga

AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

2 weeks ago - Business Wire

AngioDynamics to Report Fiscal 2022 First Quarter Financial Results on September 30, 2021

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

4 weeks ago - Business Wire

Why Is AngioDynamics (ANGO) Up 2.3% Since Last Earnings Report?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

2 months ago - Business Wire

After Beating Estimates, Is This Little-Known Medical Device Company a Buy?

AngioDynamics exceeded analyst expectations on revenue in Q4 2021, but does that make it worth buying?

2 months ago - The Motley Fool

AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top

AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.

3 months ago - Zacks Investment Research

AngioDynamics Breaks-Even In FY21, Issues Mixed Forecasts For FY22

AngioDynamics Inc (NASDAQ: ANGO) reports break-even in 4Q of 2021 with adjusted EPS of $0.00, a turnaround from EPS of (0.06) posted a year ago. The Company witnessed the pressure from COVID-19 graduall...

3 months ago - Benzinga

AngioDynamics Reports Fiscal 2021 Fourth Quarter and Full-Year Financial Results

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

3 months ago - Business Wire

AngioDynamics Announces Details for Investor & Technology Day on July 13, 2021

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

3 months ago - Business Wire

AngioDynamics to Report Fiscal 2021 Fourth Quarter and Full-Year Financial Results and Host Investor & Technology Day...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

3 months ago - Business Wire

AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?

AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.

3 months ago - Zacks Investment Research

AngioDynamics (ANGO) Receives FDA Nod for AlphaVac System

AngioDynamics (ANGO) gets 510(k) clearance from the FDA for the AlphaVac System for the non-surgical removal of thrombi or emboli from the vasculature.

4 months ago - Zacks Investment Research

AngioDynamics Receives 510(k) Clearance for AlphaVac Mechanical Thrombectomy System

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

4 months ago - Business Wire

AngioDynamics to Present at the UBS Virtual Global Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

4 months ago - Business Wire

AngioDynamics (ANGO) Up 4.3% Since Last Earnings Report: Can It Continue?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Why You Should Hold AngioDynamics (ANGO) in Your Portfolio

Investor optimism is high on AngioDynamics (ANGO) stock, courtesy of its solid prospects.

5 months ago - Zacks Investment Research

AngioDynamics Submits 510(k) Application to FDA for AlphaVac Mechanical Thrombectomy System

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology tod...

6 months ago - Business Wire

AngioDynamics to Present at the Needham Virtual Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, tod...

6 months ago - Business Wire

AngioDynamics (ANGO) Q3 Earnings and Revenues Top Estimates

AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q3.

6 months ago - Zacks Investment Research

AngioDynamics (ANGO) Soars 7.9%: Is Further Upside Left in the Stock?

AngioDynamics (ANGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

6 months ago - Zacks Investment Research

AngioDynamics (ANGO) Surpasses Q3 Earnings and Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 166.67% and 4.04%, respectively, for the quarter ended February 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Recap: AngioDynamics Q3 Earnings

Shares of AngioDynamics (NASDAQ:ANGO) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 100.00% year over year to $0.02, which beat the estimate of ...

6 months ago - Benzinga

AngioDynamics Reports Fiscal 2021 Third Quarter Financial Results and Updates Guidance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, to...

6 months ago - Business Wire